Theranostic Radiopharmaceutical Platforms Combining Therapeutic Radionuclides With Sequential Treatment Monitoring

Abstract

Theranostic radiopharmaceutical platforms represent a paradigm shift in personalized medicine, enabling simultaneous diagnosis, therapy, and sequential treatment monitoring using targeted radionuclides. By integrating therapeutic and diagnostic agents into a single molecular system, these platforms facilitate real-time assessment of treatment efficacy, optimize patient selection, and reduce unnecessary toxicities. This review synthesizes current evidence on the clinical application and scientific underpinnings of theranostic radiopharmaceuticals, focusing on their role in oncology and other relevant disease domains. We discuss epidemiological impact, molecular mechanisms, risk stratification, clinical presentation, diagnostic integration, management strategies, and emerging innovations, providing guideline-based insights for clinicians.

Introduction

Theranostics, the fusion of therapeutics and diagnostics, leverages molecular imaging and targeted radionuclide therapy to revolutionize patient care. Radiopharmaceutical platforms equipped with both therapeutic and imaging isotopes enable clinicians to visualize tumor burden, deliver cytotoxic radiation, and monitor treatment response in a seamless, patient-specific manner. This dual capability underpins a growing movement toward precision oncology and targeted management of non-malignant diseases, supporting dynamic clinical decision-making. The past decade has seen rapid expansion of theranostic agents, such as Lutetium-177-labeled peptides and PSMA-targeted compounds, with robust clinical validation across multiple tumor types. Understanding the scientific basis, clinical workflow, and evolving guidelines is critical for effective utilization of these novel platforms.

Epidemiology / Disease Burden

The global burden of cancer and refractory metastatic disease continues to rise, with an estimated 19.3 million new cases and nearly 10 million deaths worldwide in 2020. Traditional diagnostic and therapeutic paradigms are often limited by lack of specificity and the inability to monitor therapeutic efficacy in real time. Theranostic radiopharmaceuticals, particularly in neuroendocrine tumors (NETs), metastatic prostate cancer, and thyroid malignancies, address these gaps by offering targeted, patient-tailored approaches. The increasing prevalence of advanced-stage malignancies and the need for effective salvage therapies underscore the clinical importance of theranostic platforms. Furthermore, the integration of sequential treatment monitoring has the potential to improve outcomes, reduce healthcare resource utilization, and enhance quality of life for patients with otherwise limited options.

Pathophysiology

Theranostic radiopharmaceuticals exploit disease-specific molecular targets to deliver diagnostic and therapeutic radionuclides to pathological tissues. For instance, somatostatin receptor (SSTR) expression in neuroendocrine tumors enables selective uptake of radiolabeled peptides, while prostate-specific membrane antigen (PSMA) expression in prostate cancer facilitates targeted delivery of beta or alpha particle emitters. The therapeutic efficacy arises from localized radiation-induced DNA damage, apoptosis, and disruption of cellular replication, while concomitant imaging isotopes (such as Gallium-68 or Zirconium-89) permit visualization of agent biodistribution and tumor targeting. The molecular specificity of these agents minimizes off-target effects and allows for patient selection based on receptor expression, optimizing the therapeutic index.

Risk Factors

Risk stratification for theranostic radiopharmaceutical therapy is multifaceted, involving tumor biology, receptor expression, renal function, and patient comorbidities. Patients with high receptor density (e.g., SSTR2 in NETs, PSMA in prostate cancer) are most likely to benefit, whereas those with impaired renal or hepatic function may face elevated toxicity risks due to radiopharmaceutical clearance dynamics. Prior radionuclide exposure, performance status, and bone marrow reserve are additional determinants influencing eligibility and safety. Pre-therapeutic imaging with diagnostic analogs (e.g., 68Ga-DOTATATE PET/CT) is essential for identifying suitable candidates and reducing the risk of ineffective or harmful therapy.

Clinical Features

Patients considered for theranostic radiopharmaceutical platforms often present with advanced, unresectable, or metastatic disease refractory to conventional therapies. In neuroendocrine tumors, symptoms may include flushing, diarrhea, and abdominal pain, while prostate cancer patients typically report bone pain, urinary disturbances, or weight loss. Disease phenotype and clinical features guide initial workup and inform the selection of appropriate theranostic agents. Importantly, the integration of sequential imaging enables dynamic tracking of disease response, early detection of progression, and timely modification of therapeutic strategies.

Diagnosis

Accurate diagnosis and molecular characterization are prerequisites for successful theranostic intervention. Hybrid imaging modalities, such as PET/CT or SPECT/CT using diagnostic radiotracers (e.g., 68Ga-DOTATATE, 68Ga-PSMA), provide high-resolution visualization of target expression and metastatic distribution. These scans not only confirm the presence of disease but also assess suitability for radionuclide therapy, ensuring that only patients with sufficient receptor density proceed to treatment. Tumor biopsies and molecular profiling may further refine diagnosis and support personalized management decisions.

Treatment & Management

Theranostic radiopharmaceutical therapy involves administration of a radiolabeled compound designed to selectively target pathological tissues while sparing normal organs. Standard protocols include Lutetium-177-DOTATATE for SSTR-positive NETs and Lutetium-177-PSMA-617 for advanced prostate cancer, with treatment cycles typically spaced 6 to 8 weeks apart. Sequential imaging post-therapy allows for real-time monitoring of tumor response, detection of new lesions, and assessment of radiotracer biodistribution. Management also encompasses supportive care (antiemetics, nephroprotection), toxicity monitoring (hematological, renal, hepatic), and multidisciplinary team involvement to optimize patient outcomes and mitigate adverse events.

Recent Advances / Emerging Therapies

Several innovations are reshaping the landscape of theranostic radiopharmaceuticals. Alpha-emitting agents, such as Actinium-225-PSMA, offer enhanced cytotoxicity for resistant tumors with reduced collateral damage. Next-generation dual-modality probes combine PET and optical imaging, expanding intraoperative applications. Artificial intelligence-driven image analysis and dosimetry are improving response prediction and personalization. Novel targets beyond SSTR and PSMA—such as fibroblast activation protein (FAP) and CXCR4—are under investigation, broadening therapeutic potential. Additionally, the integration of immunotherapy with radionuclide treatment is being explored to synergistically boost anti-tumor immunity.

Guideline Recommendations

Recent guidelines from the European Association of Nuclear Medicine (EANM) and American Society of Clinical Oncology (ASCO) recommend theranostic radiopharmaceuticals for patients with progressive, inoperable SSTR-positive NETs or metastatic castration-resistant prostate cancer expressing PSMA. Comprehensive pre-treatment evaluation, including molecular imaging, renal function assessment, and multidisciplinary discussion, is emphasized. Sequential post-therapy imaging is advocated to monitor response, guide therapy continuation or modification, and detect early toxicities. The importance of patient selection, individualized dosimetry, and long-term follow-up is highlighted across all major guidelines.

Conclusion

Theranostic radiopharmaceutical platforms that combine therapeutic radionuclides with sequential treatment monitoring are revolutionizing the management of advanced malignancies. By uniting precise targeting, real-time assessment, and adaptable clinical strategies, these platforms embody the principles of personalized medicine. Continued research, technological innovation, and adherence to evidence-based guidelines will further expand their clinical utility, ultimately improving outcomes and quality of life for patients facing challenging diseases.